| http://www.w3.org/ns/prov#value | - However, at 12 years, the overall mortality in the two arms was not statistically significantly different (32.7% vs 39.8%).ImplicationsNo increase in benefit of radical prostatecomy was observed after 10 years.LimitationsIt is unclear whether these results would apply to today's Western male populations, who, unlike the men in the SPCG-4 trial, are diagnosed with prostate cancer mainly by prostate
|
